You are here

LEO Pharma

After transformation under new CEO, Leo Pharma touts innovation model and financial progress

Fierce Pharma

Tue, 03/12/24 - 06:49 pm

Christophe Bourdon

Eying Incyte's Opzelura, Leo Pharma shares data for JAK cream in hand eczema

Fierce Pharma

Sun, 10/15/23 - 11:52 pm

clinical trials

LEO Pharma to Acquire Timber Pharmaceuticals

Dermatology Times

Mon, 08/21/23 - 07:58 pm

Timber Pharmaceuticals

Further shuffling at Leo Pharma as dermatology drugmaker splits R&D

Endpoints

Wed, 03/15/23 - 10:05 am

Leo Pharma announces positive results for hand eczema study

Pharmaphorum

Mon, 02/13/23 - 10:23 am

clinical trials

chronic hand eczema

Leo Pharma picks Christophe Bourdon as CEO after one-year stint at failed Danish meme stock Orphazyme

Fierce Biotech

Mon, 01/31/22 - 11:42 pm

Christophe Bourdon

Leo Pharma’s Tralokinumab News: What You Need to Know

BioSpace

Thu, 05/20/21 - 11:10 pm

atopic dermatitis

FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate

Endpoints

Fri, 04/30/21 - 10:43 am

atopic dermatitis

monoclonal antibodies

LEO Pharma’s new R&D lead on driving agility in drug development

Pharmaforum

Wed, 03/24/21 - 11:22 pm

Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA

Endpoints

Tue, 07/21/20 - 10:27 am

LEO eyeing 2021 US launch for eczema drug tralokinumab

Pharmaforum

Fri, 07/10/20 - 10:47 am

AI drug discovery startup strikes partnership with LEO Pharma

MedCity News

Thu, 07/2/20 - 12:09 am

AAD 2020 – Leo’s eczema wildcard proves tame

EP Vantage

Fri, 06/12/20 - 08:02 pm

atopic dermatitis

LEO Pharma mounts another challenge to the eczema giants, betting $40M cash on a drug from China

Endpoints

Wed, 04/15/20 - 10:42 am

clinical trials

Leo's Dupixent rival hits all endpoints in pivotal program

Fierce Biotech

Wed, 12/11/19 - 10:36 am

atopic dermatitis

LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

CP Wire

Tue, 11/20/18 - 10:00 am

Gorlin Syndrome

LEO Pharma and PellePharm Announce Collaboration to Advance Rare Skin Disease Therapies Worth up to $760 Million

Tue, 11/20/18 - 09:56 am

Gorlin Syndrome

LEO Pharma Closes Acquisition of Bayer’s Prescription Dermatology Business in the US

Tue, 09/4/18 - 09:55 am

Bayer sells prescription dermatology brands to Denmark's Leo Pharma

Reuters

Tue, 07/31/18 - 10:59 pm

UTILITY Therapeutics Inks License Agreement for Two Antibiotics for the US Market

CP Wire

Tue, 05/15/18 - 09:30 am

UTILITY Therapeutics

Pages